Global Market Insights, Inc.: Insulin

Showing posts with label Insulin. Show all posts

Thursday, 8 March 2018

Antidiabetics Market to grow at 10.5% CAGR from 2017 to 2024

Antidiabetics Market growth is driven by rising geriatric population base, innovation of new drugs, increasing adoption of drugs and increased disposable income. Owing to the changes in lifestyle, even children between age group of 13-14 years are at high risk to get diabetes. It offers huge opportunities industry players. Antidiabetics Market size is set to reach USD 110 billion by 2024; according to a new research report by Global Market Insights, Inc.

Increasing number of obese and diabetic patients coupled with rising patient awareness levels serve as high impact rendering factors for antidiabetic market growth over the forecast period.

Request for a sample of this research report - https://www.gminsights.com/request-sample/detail/504

Favorable government initiatives such as Diabetes Prevention Program (DPP) that aims to help individuals with prediabetes, reduces their risk to develop type 2 diabetes. Trained lifestyle coach works with participants and communicate lifestyle skills, such as, eating healthy food, physical activity and managing stress. Such initiatives should propel industry growth over the forecast period.

Advent of new technologies in products like long acting insulin analogs as well as rapid acting with increased effectiveness should drive industry growth over the forecast timeframe. The novel insulin pen technology permits low-pain and suitable daily insulin injection that should upsurge therapy sales. Type 2 diabetes mellitus (T2DM) has strong familial aggregation, the person with a parent or sibling with disease are at high risk. People with obesity, hypertension, or dyslipidemia and women with history of gestational diabetes are also at high risk to develop T2DM.

Browse key industry insights spread across 130 pages with 55 market data tables & 8 figures & charts from the report Antidiabetics Market in detail along with the table of contents:

https://www.gminsights.com/industry-analysis/antidiabetics-market

Long-acting insulin provide basal insulin coverage. Basal insulin suppresses hepatic gluconeogenesis and prevent increase in glucose level during fasting state in insulin-deficient patients. Long acting insulin analog includes insulin glargine (Lantus) and insulin detemir (Levemir) which will drive industry growth.

Biguanides should contribute for significant revenue share in 2016. It is colorless solid and prevents production of glucose in liver. Biguanides are administered orally for the treatment of type 2 diabetes. It helps in improving sensitivity of body towards insulin and decreases amount of sugar absorbed in intestines and will increase demand for such antidiabetic drugs.

U.S. antidiabetics market size valued over USD 19.4 billion in 2016 and expected to grow significantly over the coming years. Increased healthcare expenditure along with availability of improved healthcare infrastructure and favorable reimbursement policies should drive antidiabetics market size.

Make an inquiry for purchasing this report @ https://www.gminsights.com/inquiry-before-buying/504

UK contributed for significant revenue share in 2016. The growth is attributed due to wide range of funds offered by Diabetes UK for research related to the treatment of diabetes and its complications. In November 2016, the Prime Minister introduced new Diabetes UK office on World Diabetes Day.

Japan antidiabetics market should grow at significant rate over the forecast period. Diabetic population is on rise due to lifestyle changes that will accompany economic growth and drive antidiabetic market growth. The Japan Diabetes Society (JDS) encourage progress and development of diabetes study and prevent people from disease in the country.

Brazil contributed for significant revenue share. The growth is attributed due to early adoption of insulin analogues and increased use of these products in the country.

Some of the companies operating in antidiabetics market include Eli Lilly, Pfizer, Novo Nordisk, Takeda Pharmaceuticals, Sanofi Aventis, Merck, Boehringer Ingelheim and Oramed Pharmaceuticals.

Browse Related Reports:

Precision Medicine Market Size By Technology (Big Data Analytics, Gene Sequencing, Drug Discovery, Bioinformatics, Companion Diagnostics), By Application (Oncology, CNS, Immunology, Respiratory), Industry Analysis Report, Regional Outlook (U.S., Canada, Germany, UK, France, Scandinavia, Italy, Japan, China, India, Singapore, Mexico, Brazil, South Africa, UAE, Qatar, Saudi Arabia), Application Potential, Price Trends, Competitive Market Share & Forecast, 2016 – 2023

https://www.gminsights.com/industry-analysis/precision-medicine-market

About Global Market Insights:

Global Market Insights, Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider; offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy and biotechnology.

Contact Us:

Arun Hegde
Corporate Sales, USA
Global Market Insights, Inc.
Phone: 1-302-846-7766
Toll Free: 1-888-689-0688
Email: sales@gminsights.com
Web: https://www.gminsights.com
Blog: https://gminsights.wordpress.com
Connect with us: Facebook | Google+ | LinkedIn | Twitter
Explore Our Blog @ http://algosonline.com/news

Monday, 13 November 2017

Antidiabetics Market share to grow at 10.5% CAGR from 2016 to 2024

Inherently propelled by a stringent regulatory framework, antidiabetics market is strongly characterized by the legalized norms implemented by authorized bodies such as the European CE and the FDA. Having undertaken the crucial responsibility of regulating the commercialization of antidiabetics in clinical trials, these organizations continue to strive hard to approve drugs post their testing with utmost caution and precision, which is a prime factor driving the growth of antidiabetics industry. For instance, recently, the U.S. Food and Drug Administration approved the Bydureon BCise (exenatide extended-release) injectable suspension manufactured by AstraZeneca.

Apparently, this drug is an all-new formulation of Bydureon that is available as a single-dose autoinjector device for adults suffering from Type II diabetes. The Bydureon BCise apparently underwent two clinical trials prior to obtaining the approval, thus validating the fact that antidiabetics market outlook is strictly defined by a regulatory frame of reference.

Request for a sample of this research report - https://www.gminsights.com/request-sample/detail/504

With the exponentially growing population and the prevalence of a sedentary lifestyle, a significant rise in the patient pool suffering from diabetes has been observed, which is likely to spur global antidiabetics market share. The WHO estimates that diabetes would be among the leading causes of death by 2030, which would severely strain the overall healthcare fraternity. The rising number of diabetic cases have prompted the governments across various geographies to take steps toward promoting awareness regarding this disorder. For instance, the ‘Diabetes UK’ is slated to launch one of the biggest campaigns to encourage consciousness regarding Type II diabetes.

The program will also make people aware of the harmful consequences of developing diabetes, encourage them to get screened regularly, and provide other related details. The prevalence of campaigns and awareness programs such as the aforementioned are certain to bring about a positive influence on antidiabetics market size, which was pegged at USD 49.5 billion in 2016.

Browse key industry insights spread across 130 pages with 55 market data tables & 8 figures & charts from the report Antidiabetics Market in detail along with the table of contents:

https://www.gminsights.com/industry-analysis/antidiabetics-market

In consequence to the unmet medical requirements of the healthcare fraternity and the rapid increase in the diabetic patient base, antidiabetics industry players have been concentrating on increasing their funding on research & development activities with an aim to launch novel insulin products that will efficiently treat this persistent sugar disorder. Major companies such as Sanofi Aventis, Eli Lilly, and Novo Nordisk presently predominate antidiabetic market share, pertaining to their popular brand value, wide range of products, and increased R&D investments. Many antidiabetics products that are currently in the pipeline to be commercialized are manufactured by these companies. In addition, global antidiabetics industry involves the participation of other generic manufacturers such as Pfizer, Oramed Pharmaceuticals, Inc., Takeda Pharmaceuticals, Boehringer Ingelheim, and Merck & Co. Inc.

An insight into APAC antidiabetics market trends:

The Asia Pacific region has been forecast to emerge as the potential hotbed for investors emptying their coffers in antidiabetics industry. This estimation may be attributed to the fact that the region has been witnessing a tremendous surge in the patient pool suffering from diabetes, especially in India and China. As per reliable statistics, close to nearly two decades earlier, in 2000, India stood at the top of the pyramid representing diabetes sufferers, with more than 31.7 million of its populace afflicted by the disease, while China stood at the second place with 20.8 million diabetic patients in tow. It has been forecast that by 2030, this number would increase up to 79.4 million patients in India and 42.3 million individuals in China. The estimates stand to validate that these countries would prove to be lucrative grounds for companies partaking in antidiabetics market share, as they would be able to bring forth a range of medications for treating the affliction in these regions.

Another emerging region in this continent has been touted to be Japan. The country, with its incredible healthcare infrastructure, rising penetration of technologically innovative insulin drugs, and the growing prevalence of diabetes among the geriatric populace, will serve to be a profitable growth avenue for APAC antidiabetics market.

Make an inquiry for purchasing this report @ https://www.gminsights.com/inquiry-before-buying/504

Regulatory and governmental bodies across the globe have been striving to increase public awareness regarding diabetes, which most certainly would provide an impetus to antidiabetics market. For instance, the National Institute of Diabetes and Digestive and Kidney Diseases has undertaken several education campaigns such as ‘Small Steps, Big Rewards’, ‘Control your Diabetes for Life’, etc., to increase the importance of diabetic screening, diagnosis, and treatment. Not far behind in the list of organizations is the American Diabetes Association, that has also launched several awareness programs regarding diabetes, which would help carve out a lucrative growth path for global antidiabetics market over the years ahead. In addition, the International Diabetes Federation, along with its member associations celebrate the 14th of November as ‘World Diabetes Day’, utilizing the 24-hour span to initiate awareness campaigns and other related programs. With a strong regulatory framework and governmental support in place, not to mention, the pivotal developments underlining the medical research and healthcare verticals, it is forecast that antidiabetics industry will chart a profitable growth curve over the coming seven years, with an estimated valuation of USD 110 billion by 2024.

Browse Related Reports:

https://www.gminsights.com/industry-analysis/precision-medicine-market

About Global Market Insights:

Contact Us:

Thursday, 12 October 2017

Tubeless Insulin Pump Market share to grow at 25% CAGR from 2017 to 2024

The research report “Tubeless Insulin Pump Market Size By Component (Pod/Patch, Remote, Others), By Distribution Channel (Hospitals, Pharmacies, e-Commerce, Others), Regional Outlook (U.S., Canada, Germany, UK, Spain, Italy, France, China, Japan, India, South Korea, Australia, Brazil, Mexico, South Africa, Saudi Arabia), Technology Development, Competitive Landscape & Forecast, 2017 – 2024” by Global Market Insights, Inc. says, Tubeless Insulin Pump Market size is set to exceed USD 2 billion by 2024.

Rising number of diabetic and obese patients coupled with introduction of advanced pump will serve as high impact rendering factors for the tubeless insulin pump market growth. Advent of new technologies in continuous glucose monitoring without the need for daily insulin injection doses will stimulate business growth over the forecast years. Growing adoption of minimally invasive insulin delivery methods should improve patient compliance.

Request for a sample of this research report - https://www.gminsights.com/request-sample/detail/2032

Inadequate reimbursement coverage and high long-term cost associated with tubeless insulin pump will hamper its adoption in emerging economies. Compliance to insulin therapy may reduce owing to high maintenance therapy cost.

The pods/patches tubeless insulin pump market should witness more than 20% CAGR over the coming years. Regular replacement of pods and high usage frequency will drive the escalated demand for these products.

Tubeless insulin pump remote should grow in parallel with the pods segment. Although the replacement rate of remotes is not as high as that of pods, their initial capital requirement is higher. Increasing sales of new tubeless insulin pump will fuel the significant growth of the remote market.

Distribution of tubeless insulin pump through e-commerce platforms has become the most popular medium. In 2016, e-commerce held the market share of over 50%, valuing more than USD 250 million. This online platform will witness a significant growth over the forecast period.

Browse key industry insights spread across 130 pages with 66 market data tables & 8 figures & charts from this 2017 report Tubeless Insulin Pump Market in detail along with the table of contents at:

https://www.gminsights.com/industry-analysis/tubeless-insulin-pump-market

Distribution through hospitals is less preferred medium because of the high cost of tubeless insulin pump. However, many private hospitals have recently started offering tubeless insulin pump at affordable prices, augmenting the industry growth of the tubeless insulin pump market.

U.S. tubeless insulin pump market valued over USD 200 million in 2016 and anticipated to grow significantly over the coming years. Switching of insulin pump user from tubed to tubeless should be the major growth rendering factor. Moreover, increasing adoption of tubeless pump by first time users will fuel regional industry growth.

Germany tubeless insulin pump market accounted for more than 20% of overall regional revenue share, owing to increasing number of diabetic patients and advanced healthcare system. Growing adoption of advanced technology will drive rapid industry grow over the forecast years.

Japan tubeless insulin pump market accounted for largest regional revenue share owing to its growing trend to adopt advanced technology. Rising per capita income of diabetic patients and high healthcare expenditure will promote tubeless insulin pump market growth.

Make an inquiry for purchasing this report @ https://www.gminsights.com/inquiry-before-buying/2032

China should witness lucrative growth in terms of revenue over the forecast period. Factors such as economic growth, large unaddressed diabetic population, rising disposable income, and improving healthcare facilities will propel business growth.

Brazil tubeless insulin pump market is projected to grow at 18% CAGR of over the forecast period. Availability of tubeless insulin pump in recent years will stimulate steady business expansion.

Some of the companies operating in tubeless insulin pump market are Insulet Corporation, Johnson & Johnson, Medtrum Technologies, Roche Holding, Cellnovo Group, Spring Health Solution, Debiotech, CeQur, Valeritas, and Abbott Diabetes Care.

New product launches and geographical expansion will primarily drive the industry. Key industry participants will strive to strengthen their position in this competitive market by adoption these strategies.

Browse Related Reports:

Antidiabetics Market Size By Product (Insulin [Rapid Acting, Long Acting, Premixed, Short Acting, Intermediate Acting], Alpha-Glucosidase Inhibitors, Biguanides, Sulphonylureas, GLP-1 Agonist, Meglitinides, DPP-4 Inhibitors, SGLT-2, Thiazolodinediones), By Application (Type I Diabetes, Type II & Other), Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2016 – 2023

https://www.gminsights.com/industry-analysis/antidiabetics-market

About Global Market Insights:

Contact Us:

Saturday, 7 October 2017

Tubeless Insulin Pump Market share to grow at 25% CAGR from 2017 to 2024

Citing yet another example, in 2016, Medtrum Technologies Incorporation, a key participant in tubeless insulin pump market, had launched a tubeless insulin punch fitted with CGM system. Even Roche Holdings AG, a healthcare firm based in Switzerland, in 2015, introduced the Accu-Chek Connect – a bolus calculator, in its tubeless insulin pump, that has apparently helped numerous users to calculate the proportion of insulin doses to be consumed.

Request for a sample of this research report - https://www.gminsights.com/request-sample/detail/2032

Critical agreements between prominent industry giants have ushered in new developments across tubeless insulin pump industry. Quoting an example, in 2016, Insulet Corporation and Eli Lilly & Company, a U.S. based pharmaceutical giant, had signed a pact to build a new type of OmniPod tubeless insulin delivery system to deliver Lilly’s highly concentrated U200 and U500 insulin formulations. It is undeniable therefore, that collaborations witnessed across the pharmaceutical and healthcare industry can have a major impact on the overall business.

Tubeless insulin pumps find a remarkably high demand over their tubed counterparts across the United States. This, as the experts say, is a key determinant that will facilitate the development of North America tubeless insulin pump market. In 2016 alone, U.S. tubeless insulin pump industry size was pegged at USD 200 million. The region is expected to make notable contributions toward North America tubeless insulin pump market share in the ensuing years.

https://www.gminsights.com/industry-analysis/tubeless-insulin-pump-market

Brazil tubeless insulin pump market size is slated to expand at a rate of 18% over the coming timeframe. Easy accessibility of tubeless insulin pumps with user-friendly features is expected to expand the product penetration in the region.

Europe is slated to be one of prime hubs for the development of tubeless insulin pump market. This prediction may have perhaps stemmed from the fact that the region is a model instance of highly sophisticated healthcare infrastructure. The robust improvement in healthcare services in addition to the deployment of novel technologies across the healthcare sector are projected to have a significant effect on the growth of Germany tubeless insulin pump market share. The country is expected to dominate the overall industry share in terms of revenue over the coming years.

Make an inquiry for purchasing this report @ https://www.gminsights.com/inquiry-before-buying/2032

Tubeless insulin pump industry is projected carve out a profitable growth curve over the coming years, subject to the product’s innumerable benefits. The market has been forecast to have bright growth prospects as is evident from the estimates put forth by a research study – the report apparently states that this market will grow at a rate of 25% over 2017-2024, having attained USD 350 million in 2016.

Tubeless insulin pump market is likely to be constrained by a few essential factors, such as escalating product costs and restricted insurance coverage policies. On these grounds, manufacturers have been striving to reduce equipment costs and make them affordable to attract a wider consumer base. In addition, competitive pricing strategies adopted by the key business players will further help in reducing the costs of devices, thereby propelling tubeless insulin pump market expansion.

Browse Related Reports:

https://www.gminsights.com/industry-analysis/antidiabetics-market

About Global Market Insights:

Contact Us:

Tuesday, 19 September 2017

Tubeless Insulin Pump Market share to grow at 25% CAGR from 2017 to 2024

Improved product functionality is a determinant that may incite investors to pour in their money in tubeless insulin pump industry. Insulet’s latest addition of smart features to its product is an instance of the aforementioned statement. Elaborating further, Insulet Corporation, a renowned player across tubeless insulin pump industry, has recently added additional features such as touchscreen and Bluetooth to its OmniPod Dash system. Citing yet another example, in 2016, Medtrum Technologies Incorporation, a key participant in tubeless insulin pump market, had launched a tubeless insulin punch fitted with CGM system. Even Roche Holdings AG, a healthcare firm based in Switzerland, in 2015, introduced the Accu-Chek Connect – a bolus calculator, in its tubeless insulin pump, that has apparently helped numerous users to calculate the proportion of insulin doses to be consumed.

Request for a sample of this research report- https://www.gminsights.com/request-sample/detail/2032

Browse key industry insights spread across 130 pages with 66 market data tables & 8 figures & charts from this 2017 report Tubeless Insulin Pump Market in detail along with the table of contents at:

https://www.gminsights.com/industry-analysis/tubeless-insulin-pump-market

Make an inquiry for purchasing this report @ https://www.gminsights.com/inquiry-before-buying/2032

Browse Related Reports:

Antidiabetics Market Size By Product (Insulin [Rapid Acting, Long Acting, Premixed, Short Acting, Intermediate Acting], Alpha-Glucosidase Inhibitors, Biguanides, Sulphonylureas, GLP-1 Agonist, Meglitinides, DPP-4 Inhibitors, SGLT-2, Thiazolodinediones), By Application (Type I Diabetes, Type II & Other), Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2016 – 2023

https://www.gminsights.com/industry-analysis/antidiabetics-market

About Global Market Insights:

Arun Hegde
Corporate Sales, USA
Global Market Insights, Inc.
Phone: 1-302-846-7766
Toll Free: 1-888-689-0688
Email: sales@gminsights.com
Web:https://www.gminsights.com
Blog:https://gminsights.wordpress.com
Connect with us:Facebook|Google+| LinkedIn| Twitter